FORM PTO-1449 (R v. 2-32)	U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-479-C	Serial No. 10/629,368
JAN 1 6 2004 B	• • • • • • • • • • • • • • • • • • •	Applicant: Belardinelli	
THAUE	·	Filing Date: 7/29/03	Group: Art Unit 1623

U.S. PATENT DOCUMENTS

Examin r		Document Number	Date	Name	Clas s	Subclass	Filing Date if Appropriate
Me A	7	6,026,317 •	2/15/00	Verani			
MICAA	BI	6,403,567 ◆	6/11/02	Zablocki			
	_						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Trans	lation
1							Yes	No
Re	AL1	WO 00/78778 ●	12/28/00	PCT ·				
1/c	AM1	WO 01/62979 🔌	8/30/01	РСТ				
			34.700.4	TRANSPORTER A				-

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

He	AR1	Xu, et al. "Coronary Vasodilation by a Short Acting, Low Affinity A2A Adenosine Receptor Agonist in Anesthetized Closed Chest Dogs: A Second Generation of Coronary Artery Pharmacologic Stressor", Circulation, vol. 102, no. 18, pp. 3912 (2000).

EXAMINER L. E. Crane	My Com	DATE CONSIDERED	05/19/2006
- 1			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEKNEN MULBERT & BERGHOFF 300 SOUTH WACKER DRIVE CHICAGO, ILLINOIS 80808 TELEPHONE (312) 913-0001

10/629,368 - PTO-1449 #1 COPY FOR [] File (Applicant

	OPEN			
FORM PTO-1449 (Rev. 2-32)	AUG 2 7 2004	* U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
,	STATEMENT BY A	SCLOSURE APPLICANT	02-479-C	10/629,368
	(Use several sheets	if necessary)		
		72 .	Applicant:	
			Belardinelli	
			Filing Date:	Group:
			7/29/03	Art Unit 1623 8737

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Clas	Subclass	Filing Date if Appropriate
Me	AA2		9/11/90	Miyasaka et al			
1	AB2	4,968,697	11/6/90	Hutchison			
	AC2	2.070,077	12/10/91	Mohiuddin et al	<i>-</i>		
	AD2	5 400 007	2/23/93	Miyashita et al.			
	AE2		12/14/93	Kogi et al			
	AF2	5 450 054	10/17/95	Yamaguchi et al.			
	AG2		1/14/97	Cristalli			
	AH2	5,705,491	1/6/98	Yamada			
	AI2	<u></u>	6/23/98	Khan et al.			
	AK2	5,939,543	8/17/99	Morozumi et al.			
	AL2	6,214,807	4/10/01	Zablocki et al.			
Me.	AM2	US2004/0127533	7/1/04	Hart et al.			
// C.	JAMZ		N DATENT	DOCUMENTS	· · · · · · · · · · · · · · · · · · ·		

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Trans	lation
							Yes	No
The	AN2	WO 93/25677	12/13/93	РСТ				

						•	
EXAMINER	L.	E.	Crane	• • •	DATE CONSIDERED	05/19/2006	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHNEN HULBERT & BERGHOFF 300 SOUTH WACKER DRIVE CHICAGO, ILLINOIS 60606 TELEPHONE (312) 913-0001

COPY FOR [] File [()] Applicant

FORM PTO-1449 (Rev. 2-32) INFORMATION D STATEMENT BY (Use several sheets	Patent and Trademark Office ISCLOSURE APPLICANT	Atty. Docket No.	Serial No. 10/629,368
		Applicant: Belardinelli Filing Date: 7/29/03	Group: Art Unit 1623

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Trans	lation
		S Aus					Yes	No
M	A02	WO 00/78779	12/28/00	PCT				
	AP2	WO 04/011010	2/5/04	PCT.				
	AQ2	EP 0354 638	2/14/90	EP .				
	AR2	965,411	4/1/75	CA		1		
Jet	AS2	Hei 5[1993]-9197	1/19/93	JP	T	İ		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc).

g/re	AT2	Iskandrian, A, "Adenosine Myocardial Perfusion Imaging", The Journal of Nuclear Medicine", vol. 35, pp. 734-736 (1994).
	AU2	Gao, et al., "Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists", <i>Journal of Pharmacology and Experimental Therapeutics</i> , vol. 298, pp. 209-218 (2001).
	AV2	Marumoto, et al., "Synthesis and Coronary Vasodilating Activity of 2-Substituted Adenosines", Chem. Pharm. Bull. 23(4): 759-774 (1975).
<i>]</i> :	AW2	Marumoto, et al., "Synthesis and Enzymatic Activity of Adenosine 3',5'-Cyclic Phosphate Analogs", Chem. Pharm. Bull. 27(4) 990-1003 (1979).
	AX2	Persson, et al., "Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives", Bioorganic & Medicinal Chemistry, 3:1377-1382 (1995).
	AY2	Mager, et al., "Molecular simulation applied to 2-(N'alkylidenehydrazino)- and 2-(N'- aralkylidenehydrazino) adenosine A₂ Agnonists", Eur J. Med. Chem, 30:15-25 (1995).
	AZ2	Cristalli et al., "2-Alkyni Derivatives of Adenosine 5'-N'ethyluronamide: Selective A2 Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation", J. Med. Chem, 37:1720-1726 (1994).
Me	BA2	Matsuda, et al., "Nucleosides and Nucleotides. 103. 2-Alkynyladenoines: A Novel Class of Selective Adenosine A ₂ Receptor Agonists with Potent Antihypertensive Effects", <i>J. Med. Chem.</i> 35:241-252 (1992).

EXAMINER	L.	E.	Crane	_	AS	lenne	 DATE CONSIDERED	05/19/2006
				 $\overline{}$				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHNEN HULBERT & BERGHOFF 300 SOUTH WACKER DRIVE CHICAGO, ILLINOIS 60606 TELEPHONE (312) 913-0001

Applicant

1 Paris ...

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ne Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** Filing Date INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

Sheet 1

10/629,368 7/29/2003 First Named Inventor Belardinelli Art Unit 1623 3737 **Examiner Name** Not Assigned Attorney Docket Number 02-479-C

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
The	AA3=	US- 2004/0064039	4-1-04	Belardinelli	
		US-			
7		US-			
		US-			
-1		US-		- /	-
		US-			
		US-			
$\neg T$		US-			
$\neg \tau$		US-			-
		US-			
T		US-			
\neg		US-			
7		US-			
7		US-			,
7		US-			
7		US-			
1		US-	1.		
		US-			
		US-			

		FORE	GN PATENT DOCU	MENTS		
Examiner Cite Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	🏻
			and the second of	٠.		Γ
				·		Г
						Г

Examiner 05/19/2006 Signature L, E. Crane Considered

*EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 (1-800-786-9199) and select option 2.

COPY FOR [] File [Applicant

WIR O . TOTA !

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

14 H	ite for form 1449/PTO				required to respond to a collection of information unless it contains a valid OMB control number Complete If Known				
0050111	10 10 10 11 17 17			Application Number	10/629,368				
INF	ORMATION	I DIS	SCLOSURE	Filing Date	7/29/03				
STA	ATEMENT I	3Y A	PPLICANT	First Named Inventor	Belardinelli				
	(Iba'aa maay ah	4		Art Unit	3737 - 1623				
	(Use as many sh	pers as r	19C6SS27Y)	Examiner Name	Not Assigned				
Sheet	2	of	2	Attorney Docket Number	02-479-C				

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ²
Inc.	AR3	dadbabaie;et-al: "Myocardial-perfusion-imaging with a nevel selective A2A adenosine receptor agoanists (CVT-3146): Imporant differences in radiotracer behavior, JACC, p. 443-4	
Inc.	AS3	Zhao et al, "Comparative Profile of Vasedilation by GVT-3146, a Novel A2A Receptor Agonist, & Adenosine in Conscious Dogs", Jour. of Pharm & Experimental Therapeutics, p. 182-9	
Inc.	AT3	Trochu et al. "Selective A2A Adonosine Receptor Agenist as a Coronary Vasodilator in Conscious Dogs: Potential for Use in Myocardial Perfusion Imaging, " Jour. of Cardiovasc.	
		·	
		•	
		• • • • • • • • • • • • • • • • • • • •	

Examiner Signature L. E. Crane Mol Cause Date Considered 05/19/2006

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Inc. - Incomplete citaten: missing bibliographic information including volumn numbers, dates of publication, etc.

COPY FOR [] File [X] Applicant

使变化

[&]quot;EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is stached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (07-05)

Approved for use through 08/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Stitute for form 14498/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	Complete if Known	
Application Number	10/629,368	
Filing Date	July 29, 2003	
First Named Inventor	Belardinelli	
Art Unit	3737 1623	
Examiner Name	Not Assigned	
Attorney Docket Number	02-479-C	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
The	AR4	Glover et al. "Pharmacological Stress Thallium Scintigraphy with 2- Cyclohexylmethylidenehydrazinoadenosine", Circulation, pp.1726-1732 (1996)	
\perp			
		Simple of Address of the Control of	
 		,	

Examiner L. E. Crane Date 05/19/2006					
The second secon	Examiner Signature	L. E. Crane	7/1/m	Date Considered	05/19/2006

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc. www.USCourtForms.com

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

APR 1 1 2006

PTO/SB/08a (07-05)

Approved for use through 07/31/2008, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the anerwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

A PAGEMANA ite for form 1449A/PTO

Same Tab

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/629,368 Filing Date July 29, 2003 First Named Inventor Belardinelli Art Unit 3737 1623 **Examiner Name** Not Assigned

(Use as many sheets as necessary) Attorney Docket Number 02-479-C 11 Sheet

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	No.1	Number-Kind Code ^{2 (If known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-			Section 19 10 Se	
		US-		,#4, ·	Suited significantly and in the description of the Photon Country	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
1		US-				
<u></u>		US-				
		US-				
		US-				
		US-				

		FOREIGN F	ATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Me	AL 5	WO 98/57651	12-12-98	Martin et al.		
73	AM5	WO 98/52611	11-26-98	Ozaki et al.		X
The	AN ₅	JP S48-26038	8-3-73	Honjoki		Х
_			2			

Examiner Date. L. E. Crane Considered Signature 05/19/2006 ruce

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, inc. www.USCourtForms.com

COPY FOR [] File // Applicant

M. Cake